GET A QUOTE

EBV VCA IgA ELISA Kit

  • Created on the 18 July, 2017.

BACKGROUND

Epstein–Barr virus viral-capsid antigen (EBV-VCA) has an important role in providing the viral capsid of the Epstein–Barr virus (EBV). This antigen is targeted by anti-VCA antibodies and these antibodies are crucial in the diagnosis of infectious mononucleosis using many different serology testing methods. Elevated levels of anti-VCA IgG antibodies is a good indicator of prior infection whereas elevated levels of anti-VCA IgM can indicate acute infection. The anti-VCA IgM appears early during an EBV infection and it tends to disappear between 4-6 weeks, whereas anti-VCA IgG is present during the acute phase of EBV infections (peaks between 2-4 weeks and persist throughout a person life). Clinical findings of infectious mononucleosis can be identified in conjunction with the appearance of IgM and IgG anti-VCA antibodies. Also, for primary infections, the sensitivity of IgM and IgG anti-VCA testing are regarded as being 100% reliable.

INTENDED USE

Human EBV VCA-IgA ELISA kit is intended for detecting in-vitro quantitative amounts of human IgA antibodies to Epstein–Barr virus viral-capsid antigen (EBV VCA) using serum and plasma. This assay has a minimum analytical sensitivity limit of 1.0 U/ml.

SENSITIVITY

The minimum detection sensitivity level of human Epstein–Barr virus viral-capsid antigen (EBV VCA) IgA using this human EBV VCA IgA ELISA kit was 1.0 U/ml. The dynamic assay range for this kit is 1.0 – 125.0 U/ml.

REFERENCES

  1. A meta-analysis on the EBV DNA and VCA-IgA in diagnosis of Nasopharyngeal Carcinoma. Pak J Med Sci. (2013) 29 (3): 885-90. Review. Song C. and Yang S.
  2. Correlation Analysis of Nasopharyngeal Carcinoma TNM Staging with Serum EA IgA and VCA IgA in EBV and VEGF-C and -D. Med Sci Monit. (2015) 21: 2105-9. Sun R., et al.
  3. Expression of Serum Sialic Acid, Early Antigen-IgA, and Viral Capsid Antigen-IgA in Nasopharynx Cancer Patients: The Diagnostic Implication of Combined Assays. Med Sci Monit. (2015) 21: 4068-73. Sun Y., et al.
  4. Development of a time-resolved fluoroimmunoassay for Epstein-Barr virus viral capsid antigen IgA antibody in human serum. J Virol Methods. (2015) 222: 16-21. Liang Q.N., et al.
  5. Evaluation of a semi-quantitative ELISA for IgA antibody against Epstein-Barr virus capsid antigen in the serological diagnosis of nasopharyngeal carcinoma. Int J Infect Dis. (2014) 25: 110-5. Chen H., et al.
  6. Increased incidence of IgA antibodies to the Epstein-Barr virus-associated viral capsid antigen and early antigens in patients with chronic lymphocytic leukemia. Int J Cancer. (1986) 38 (1): 55-9. Dölken G., et al.

ADDITIONAL INFORMATION

  • Full Name: EBV VCA IgA ELISA Kit
  • Reactivity: Human
  • Sample Type: Plasma, Serum
  • Sensitivity: 1.0 U/ml

OTHER RELATED ELISA KITS

TESTIMONIALS arrow icon

Your secretory IgA ELISA kit gave good results and I was also really impressed with how quickly we received it.

L. Johnston
PhD Student / University of Glasgow

It is refreshing to know that you have a technical team that is very knowledgeable. I have already recommended your company to other researchers in our department.

Dr. P. Anderson
Lecturer / University College London (UCL)

I am a first time user and found that your instruction manual was very easy to follow. The insulin ELISA kit performed well and I was happy with the results that were generated.

J. Thomas
Senior Technician / Addenbrooke’s Hospital

I carried out a pilot study comparing the performance of many ELISA kits from different suppliers and found your kits to be one of the better performers. We observed good linearity and tight replicates.

Dr. C. Davies
Lead Scientists / AstraZeneca

You are my first point of contact when I am looking to purchase ELISA kits. You have such an easy and simple system, yet it is very effective.

A. Shaw
Purchasing / University of Oxford